FARN:LON
Faron Pharmaceuticals Oy
GBX 36,07
arrow_downward
-1,18%(-0,43) 1G
1 Eki, 17:44:12 GMT+1 · GBX
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoFARN ile ilgili en önemli analizler oluşturuluyor...
Açık
GBX 37,75
Yüksek
GBX 38,00
Düşük
GBX 34,00
Piy. değ.
73,18 Mn
Ort. hacim
49,09 B
İşlem Hacmi
40,17 B
52 haftalık en yüksek
GBX 193,58
52 haftalık en düşük
GBX 34,00
HBK
-GBX 0,10
Tedavüldeki hisse senedi sayısı
31,03 Mn
Çalışan sayısı
36
Açık
GBX 37,75
Yüksek
GBX 38,00
Düşük
GBX 34,00
Piy. değ.
73,18 Mn
Ort. hacim
49,09 B
İşlem Hacmi
40,17 B
52 haftalık en yüksek
GBX 193,58
52 haftalık en düşük
GBX 34,00
HBK
-GBX 0,10
Tedavüldeki hisse senedi sayısı
31,03 Mn
Çalışan sayısı
36
Haberler
Web kaynaklarından ve haber iş ortaklarından
Simply Wall Street
·
8 dakika önce
EquipmentShare.com (EQPT) Commits To 1 Gigawatt Of Power Capacity
TradingView
·
39 dakika önce
S&P 500, Nasdaq, Dow Futures Inch Higher As Investors Cheer Cooling Yields — GOOGL, MU, MAT, NVDA In Focus
MarketWatch
·
56 dakika önce
Here’s who’s joining the S&P 500 in the index’s latest shakeup
Fox Business
·
2 saat önce
October could be a huge month for the stock market. Here's why.
Profil
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Faron Pharmaceuticals Oy hakkında